Cipla fell 2.48% to Rs 414.80 after it informed that the company has received a warning letter from USFDA for its Goa facility.
The United States Food and Drug Administration (USFDA) had inspected Cipla's Goa facility from 16 to 27 September 2019.
The company said that it remains committed to maintaining the highest standards of compliance and will work closely with the agency to comprehensively address all the observations.
Cipla is a global pharmaceutical company. It strengths lie in the respiratory, anti-retroviral, urology, cardiology, anti-infective and CNS segments.
Powered by Capital Market - Live News